APCCC 2019 PRESENTATION SLIDES

Get Free Access to Session Slides

APCCC 2019 VL

The Neuroendocrine Prostate Cancer Spectrum Diagnosis and Treatment Presentation - Eleni Efstathiou

Details
Eleni Efstathiou presents an overview of neuroendocrine prostate cancer during the Management of Castration-Resistant Prostate Cancer (CRPC) session at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Dr. Efstathiou touches on the inaccuracies in the terminology of neuroendocrine prostate cancer, the current state of aggressive variant prostate cancer, where efforts are in place to...

Immunotherapy for Metastatic Castration Resistant Prostate Cancer Presentation - Charles Drake

Details
Charles Drake presented on immunotherapy for metastatic castration-resistant prostate cancer (mCRPC) during the Management of Castration-resistant Prostate Cancer (CRPC) session at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. He reviews several immunotherapy trials including the first major successful trial in immunotherapy for prostate cancer, the IMPACT trial in 2010 which led...

Imaging Bone (Flare) Responses in Advanced Prostate Cancer Presentation - Anwar Padhani

Details
Anwar Padhani presents at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 on imaging and flare responses when assessing patients with metastatic castration-resistant prostate cancer (mCRPC). In his presentation, Dr. Padhani notes that bone scans/CT scans lead to poor confidence for knowing the true clinical states and assessing therapy benefits for bone disease in advanced prostate...

Which Systemic Therapy for Which Patient with Newly Diagnosed Metastatic Prostate Cancer Presentation - Chris Sweeney

Details
Christopher Sweeney presents on systemic therapy for prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). The spectrum of patients starting androgen deprivation therapy (ADT) for metastatic disease is quite vast. Discussing several treatments and several studies as well as their overall survival treatment benefit Dr. Sweeney focuses on which systemic therapy for which...

Optimal Glucocorticoid Regimen with Abiraterone Acetate Presentation - Gert Attard

Details
The aim of this presentation by Gerhardt (Gert) Attard at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 was to provide the research community with the information required to make the right choice on the dose and regimen of prednisone to combine with abiraterone and indications for combining dexamethasone with abiraterone, how to maximize therapy of steroids with abiraterone aceta...

Integrating Advanced Molecular Imaging into Clinical Practice - Michael Morris

Details
Michael Morris joins Alicia Morgans to discuss advanced molecular imaging, and how we can take the data we have and integrate it into our clinical practices. They discuss recent results of the Prostate Cancer Working Group as well as the patient where advanced molecular imaging is most useful. Finally, Dr. Morris provides his recommendation to clinicians gaining access to these scans and how to us...

Results and Lessons Learned from the Consensus Conference for Developing Countries - Fernando Maluf

Details
Fernando Maluf joins Charles Ryan to discuss the data from the first Prostate Cancer Global Consensus Conference for Developing Countries. This was a tremendous achievement in which more than a hundred physicians from all over the world, particularly from developing countries in Latin America, Africa, and the Middle East participated. Physicians that participated included several specialties: urol...

Integrating Genomics and Genetics into Clinical Care for Prostate Cancer, A Pathologist's Perspective - Colin Pritchard

Details
In the era that genomics and genetics are really making an impact to clinical practice and with the recent positive results of the PROfound study, Alicia Morgans and Colin Pritchard have a discussion thinking about this data, how do we implement it, and how do we work with our pathologists to make things happen? Colin highlights this game-changing genomic markers data, particularly for homologous...

Follow Up of ADT Alone vs. ADT "Plus" Presentation - William Oh

Details
During the Management of Metastatic Castration-sensitive/naive Prostate Cancer session at the 2019 Advanced Prostate Cancer Consensus Conference, William Oh presented the use of androgen deprivation therapy (ADT) alone vs. the use of ADT in addition to one of the available systemic therapies for metastatic prostate cancer. Biography: William Oh, MD Chief of Division of Hematology and Medical Oncol...

Addition of AR Pathway Inhibitors vs. Docetaxel: Statisticians' Perspective Presentation - Matthew R Sydes

Details
During the Management of metastatic castration-sensitive/naive prostate cancer session at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC), Matthew Sydes presented a statisticians' perspective on Addition of AR pathway inhibitors vs. docetaxel. Video Length 10:53 minutes Biography: Matthew R Sydes, MSc CStat CSci, MRC Clinical Trials Unit at UCL London Related Content: Written Confer...